Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Feb 20, 2007

Pro-Pharmaceuticals Works with Chemwerth to Scale Up Davanat

  • Pro-Pharmaceuticals is collaborating with Chemwerth to scale up production of its lead drug candidate, Davanat®, to 100 kilograms for initial marketing needs. 

    Davant is a carbohydrate polymer composed of mannose and galactose (galactomannan). Pro-Pharmaceuticals believes  that its mechanism of action is based upon binding to lectins on the cell surface. It thus theorizes that the product targets specific lectin receptors that are over-expressed on cancer cells.

    Current research indicates that Galectins affect cell development and play important roles in cancer, including tumor cell survival, angiogenesis, and tumor metastasis, according to a Pro-Pharmaceuticals. The company hence believes that this form of targeted delivery may allow for higher doses of chemotherapy administration with no increase in toxicity.



Be sure to take the GEN Poll

CRISPR Patent Controversy

Do you think recently released email from a former Broad Institute scientist to Jennifer Doudna will expedite a final legal decision on who owns the CRISPR patent?

More »